Clinical trials: Intravascular Volume
Hemorrhage
Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume
This study is designed to validate implementation of the CRI algorithm in the CypherOx CRI system. Healthy human subjects will undergo progressive reduction in central blood volume to the point of hemodynamic instability (defined…
- Trial name
- NCT01935427
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Flashback Technologies
Hemorrhage
Comparison of Compensatory Reserve Index to Changes in Stroke Volume and Intravascular Volume
The purpose of this study is to demonstrate the correlation of the Compensatory Reserve Index (CRI) numeric and graphical trend readings to intravascular volume changes as compared to graded blood loss (removal of 20% of…
- Trial name
- NCT02980471
- Testing
- Pulse Oximeter
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Flashback Technologies
Intensive Care
Measurement of Cardiac Output and Intravascular Volume Status in Children Using COstatus (SH)
Assessment and monitoring of cardiac function in the pediatric intensive care unit (PICU) is an integral part of hemodynamic monitoring of critically ill patients whether it is done directly or indirectly.
- Trial name
- NCT01613859
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Transonic Systems Inc.
Intraoperative Complications
Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation
There are no standardized plasma volume replacement protocols during liver transplantation surgery. The current study is designed to compare efficacy, safety, and costs of perioperative volume replacement with Voluven…
- Trial name
- NCT00308100
- Testing
- Hydroxyethylstarch 130/0.4, 5% Albumin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fresenius Kabi
Hypercholesterolemia, Acute Coronary Syndrome
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
Primary Objective: To compare the efficacy of alirocumab (Praluent®) with standard of care (SoC) on coronary atheroma progression (percent change in normalized total atheroma volume [TAV]) after 9 months of treatment in…
- Trial name
- ODYSSEY J-IVUS (NCT02984982)
- Testing
- Alirocumab SAR236553, Atorvastatin, Rosuvastatin
- Where
- 39 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Sanofi